Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Good afternoon Ate community

<< Previous

Bullboard Posts

Next >>

Comment by Layth1990on May 12, 2021 3:47pm

167 Views

Post# 33184742

RE:RE:Good afternoon Ate community

<p> To be clear , I don't tell people to invest in ATE. Each person is responsible for his/her own actions and must reaearch before. i'm not a financial advisor at the end. </p> <p> Spaming negativity on the other hand will harm ATE And its investors by driving price down. Also, There is no sense or evidence in what they are posting. </p>

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments